| SES # | Topics | READINGS |
|---|---|---|
| Fall 2005 | ||
| 1 | Authorship Speaker Dr. Julie Ingelfinger, Professor of Pediatrics, Harvard Medical School and Deputy Editor, New England Journal of Medicine |
Drazen, Jeffrey M., and Gregory D. Curfman. "On Authors and Contributors." N Engl J Mcd 347 (2002): 55. Kempers, R. D. "Ethical issues in biomedical publications." Fertil Steril 77 (2002): 883-888. |
| 2 | Ethical and Professional Conduct Issues in Engineering Breakthrough Medical Technologies Speaker John Abele, founder and Chairman of Boston Scientific Corporation |
Hashimoto, H., et al. "The diffusion of medical technology, local conditions, and technology re-invention: A comparative case study on coronary stenting." Health Policy (February 10, 2006). [e-pub ahead of print.] Libeer, J. C. "Role of external quality assurance schemes in assessing and improving quality in medical laboratories." Clin Chim Acta 309 (2001): 173-177. |
| 3 | HST Graduate Program Design and Administration Speaker Dr. Sangeeta Bhatia, an HST Graduate and Recent Addition to the Faculty at HST |
National Academy of Sciences. Committee on Science, Engineering, and Public Policy. On Being a Scientist: Responsible Conduct in Research. Washington, DC: National Academy Press, 1995. |
| 4 | Case Studies on Funding Ethical Issues in Academia and the Clinic Speaker Dr. John Parrish, Chairman of Dermatology for the Harvard Teaching Hospitals, Founder and Former Director of the Wellman Labs for PhotoMedicine, and Founder and Director of the Center for the Integration of Medicine and Innovative Technology (CIMIT) |
Chadwick, R., and U. Schuklenk. "Sleeping with the enemy? Where to draw the line on research funding?" Bioethics 19 (2005): iii-iv. Cichy, K. A. "Ethical implications of for-profit corporate sponsorship of research." SRA J 22 (1990): 23-27. |
| 5 | Ethical Dilemmas Associated with Drug Development for Small Target Groups Speaker Dave Fleming, Senior VP of Genzyme |
Gericke, C. A., A. Riesberg, and R. Busse. "Ethical issues in funding orphan drug research and development." J Med Ethics 31 (2005): 164-168. Hughes, D. A., B. Tunnage., and S. T. Yeo. "Drugs for exceptionally rare diseases: do they deserve special status for funding?" QJM 98 (2005): 829-836. |
| 6 | Ethical Issues Related to Clinical Research in High Stress Environments Speaker Kris Olson, MD |
Bjerneld, M., et al. "Perceptions of work in humanitarian assistance: interviews with returning Swedish health professionals." Disaster Manag Response 2 (2004): 101-108. |
| Spring 2006 | ||
| 7 | Ethics of Closed-loop Medical Control Systems Speaker Prof. John Guttag, Senior Professor of Electrical Engineering and Computer Science at MIT |
Shoeb, A., et al. "Patient-specific seizure onset detection." Epilepsy Behav 5 (2004): 483-498. |
| 8 | Ethics of Pharmaceutical Post-market Surveillance Speaker Dr. Frank Douglas, Executive Director of the Center for Biomedical Innovation Management, MIT |
Abraham, J., and C. Davis. "A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy." Soc Sci Med 61 (2005): 881-892. |
| 9 | Ethical Considerations in Accelerating Medical Technologies Speaker Dr. Wendy Everett, President of the New England Healthcare Institute (NEHI) |
|
| 10 | Ethics of Live-sustaining Biomedical Engineering Design Speaker Dr. David Lederman, Founder and Former Chairman of ABIOMED |
|
| 11 | The Good Works Project and Ethical Conduct of Research Speaker Dr. Howard Gardner, John H. and Elisabeth A. Hobbs Professor of Cognition and Education at the Harvard Graduate School of Education |
|
| 12 | The Ethics of Genetic Screening for Therapeutic Procedures | |
